Application of lactobacillus nutrient composition in preparation of medicine for preventing and treating sepsis acute lung injury

Abstract

The invention provides application of a lactobacillus nutrient composition in preparation of a medicine for preventing and treating sepsis acute lung injury. The lactobacillus nutrient composition is prepared from a low-carbon water and high-fat nutrient and mixed lactobacillus. The mixed lactobacillus comprises lactobacillus reuteri and lactobacillus plantarum, and the low-carbon water and high-fat nutrient and the mixed lactobacillus are mixed according to the mass ratio of (100-200): 1. Clinical experiments show that the lactobacillus nutrient composition disclosed by the invention can be used for improving the lung injury condition of a sepsis patient, increasing the oxygenation index and reducing the Murray lung injury score. Animal experiments show that the product can obviously inhibit lung inflammatory cell infiltration, inflammatory factors and MPO (myeloperoxidase) production on the animal level, and can be used for preparing the medicine for preventing and treating acute lung injury caused by sepsis.

Description

TECHNICAL FIELD

[0001] The present application relates to medical products containing organic active ingredients, and in particular to the application of a lactobacillus nutrient composition composed of low-carbohydrate high-fat nutrients and mixed lactobacillus in the preparation of drugs for preventing and treating sepsis acute lung injury. BACKGROUND

[0002] Sepsis is a systemic inflammatory response syndrome caused by the invasion of pathogenic microorganisms such as bacteria into the body. In addition to the manifestations of systemic inflammatory response syndrome and primary infection foci, severe sepsis can lead to organ failure and hypotension, resulting in more severe sepsis shock and further persistent hypotension. Sepsis has a high incidence, with more than 180 million cases of severe sepsis worldwide each year, and this number is rising at a rate of 1.5% to 8.0% per year. Although the continuous development of medical technology in recent years, such as anti-infection treatment and the progress of organ maintenance systems, has indeed helped the treatment of patients, the mortality rate of severe sepsis and sepsis shock is still more than 50%. Sepsis is a dangerous condition with a high mortality rate, and is one of the important causes of death in critically ill patients. The clinical treatment of sepsis is as follows: 1. Infection control: first identify the infection site, such as the lungs, abdominal cavity, etc., and perform surgical resection or fluid drainage of the affected site according to the patient's condition. 2. Hemodynamic management: commonly used treatment methods include fluid resuscitation and vasoactive drug (such as norepinephrine, vasopressin, etc.) intervention. 3. Organ function support: commonly used treatment methods include mechanical ventilation, blood purification, and extracorporeal membrane oxygenation, etc. 4. Other treatments: commonly used treatment methods include blood glucose control, glucocorticoid intervention, and anticoagulant therapy, etc.

[0003] Low-carbohydrate high-fat nutrients (i.e. low-carbohydrate, high-fat diet, referred to as LCHF) is a dietary pattern that adjusts metabolic patterns by reducing carbohydrate intake and increasing the proportion of healthy fats. Its core is to use fat as the main energy source, replacing the traditional glucose energy supply mode.

[0004] Lactobacillus reuteri is a probiotic widely present in the intestines of humans and animals, belonging to the genus Lactobacillus. It plays an important role in maintaining intestinal health and regulating the immune system, and has become one of the research and application hotspots in recent years. Lactobacillus plantarum is a gram-positive lactic acid bacteria widely present in nature, belonging to the genus Lactobacillus. It is commonly found in fermented foods (such as pickles, yogurt, cheese), plant materials, and the intestines of humans and animals, and is one of the important strains of probiotics research.

[0005] Up to now, there is no related research on the combination of low-carbohydrate high-fat nutrients and lactobacillus composition for preparing a medicine for preventing and treating sepsis acute lung injury. SUMMARY

[0006] The present application aims to solve the problems of the prior art and provide a new application of lactobacillus nutrient composition in preparing a medicine for preventing and treating sepsis acute lung injury.

[0007] The present application provides an application of lactobacillus nutrient composition in preparing a medicine for preventing and treating sepsis acute lung injury. The lactobacillus nutrient composition is composed of low-carbohydrate high-fat nutrients and mixed lactobacillus.

[0008] The low-carbohydrate high-fat nutrients and the mixed lactobacillus are mixed in a mass ratio of 100-200:1.

[0009] The low-carbohydrate high-fat nutrients, referred to as LCHF, are the commercially available Ruineng nutrients, and the nutritional composition is 15%-20% protein, 50%-60% fat, and 25%-35% carbohydrate.

[0010] The mixed lactobacillus is composed of resistant dextrin, Lactobacillus reuteri and Lactobacillus plantarum, and the resistant dextrin accounts for 97%-98%, the mixed lactobacillus accounts for 2%-3%, and the mass ratio of Lactobacillus reuteri to Lactobacillus plantarum is 1:1-1.5.

[0011] The preparation method of the lactobacillus nutrient composition is as follows: adding mixed lactobacillus powder to low-carbohydrate high-fat nutrients in a suitable ratio, and stirring to mix uniformly.

[0012] According to some embodiments of the present application, the lactobacillus nutrient composition can improve the oxygenation index of sepsis patients.

[0013] According to some embodiments of the present application, the lactobacillus nutrient composition can reduce the Murray lung injury score of sepsis patients and reduce the ICU hospitalization time of sepsis patients.

[0014] According to some embodiments of the present application, the lactobacillus nutrient composition can increase the survival rate of sepsis mice.

[0015] According to some embodiments of the present application, the lactobacillus nutrient composition can significantly inhibit the lung inflammatory cell infiltration of a sepsis mouse model.

[0016] According to some embodiments of the present application, the lactobacillus nutrient composition can inhibit the production of inflammatory factors in sepsis mice with acute lung injury. The inflammatory factors include but are not limited to IL-6, TNF-alpha and IL-1 beta.

[0017] According to some embodiments of the present application, the Lactobacillus nutrient composition can significantly inhibit the production of myeloperoxidase (MPO).

[0018] Therefore, the Lactobacillus nutrient composition described above can be applied to the preparation of a medicine for preventing and treating sepsis and acute lung injury associated with the disease.

[0019] A medicine for preventing and treating sepsis acute lung injury, comprising the Lactobacillus nutrient composition and a pharmaceutically acceptable carrier, excipient, adjuvant or a combination thereof.

[0020] The Lactobacillus nutrient composition or the medicine composition is applied in the preparation of a medicine, wherein the medicine can be used for preventing, treating or alleviating sepsis acute lung injury.

[0021] The sepsis acute lung injury described in the present application is a kind of injury of alveolar epithelial cells and capillary endothelial cells caused by sepsis, which causes diffuse pulmonary interstitial and alveolar edema, and further causes acute hypoxic respiratory failure. Through the above technical scheme, the low-carbohydrate high-fat nutrient and mixed lactobacillus (Lactobacillus reuteri and Lactobacillus plantarum) are combined to synthesize a lactobacillus nutrient composition. The mixed lactobacillus can decompose the oleic acid rich in the nutrient by releasing flavin monooxygenase to produce active substances, thereby reducing the acute lung injury caused by sepsis. The present application takes the sepsis mouse model as an example to prove that the Lactobacillus nutrient composition can significantly improve the lung injury of sepsis mice, and it is also applicable to sepsis acute lung injury caused by sepsis and has the same effect. It is disclosed that the Lactobacillus nutrient composition has a new use in preventing and treating sepsis acute lung injury.

[0022] The present application prepares a sepsis mouse model, and uses a Lactobacillus nutrient composition composed of low-carbohydrate high-fat nutrient and mixed lactobacillus (Lactobacillus reuteri and Lactobacillus plantarum) for intervention. Through detection and statistical analysis of lung function indicators, inflammatory factors and lung inflammatory cell infiltration of mice, it is found that the Lactobacillus nutrient composition intervention can improve the lung injury of sepsis mice and increase the survival rate of sepsis mice.

[0023] Compared with the prior art, the present application has the advantages and beneficial effects that:

[0024] (1) The present application uses low-carbohydrate high-fat nutrient and mixed lactobacillus (Lactobacillus reuteri and Lactobacillus plantarum) to synthesize a Lactobacillus nutrient composition according to a certain mass ratio. It can be used for preventing and treating sepsis and acute lung injury caused by sepsis.

[0025] (2) The clinical experiment shows that the lactobacillus nutrient composition can improve the lung injury of the sepsis patient, improve the oxygenation index and reduce the Murray lung injury score. The animal experiment shows that the lactobacillus nutrient composition can obviously inhibit the lung inflammatory cell infiltration, the inflammatory factor and the myeloperoxidase (MPO) production.

[0026] (3) The method is simple and convenient, the low-carbohydrate high-fat nutrient is mixed with the mixed lactobacillus (Lactobacillus reuteri and Lactobacillus plantarum) uniformly, and then can be directly implanted into the sepsis group for treatment, without complex process and expensive equipment, so that the cost is low, and the method is easy to scale production, and has good practical value and application prospect. BRIEF DESCRIPTION OF DRAWINGS

[0027] Figure 1 is a result graph of the lactobacillus nutrient composition of the application capable of improving the oxygenation index of the sepsis patient.

[0028] Figure 2 is a result graph of the lactobacillus nutrient composition of the application capable of reducing the Murray lung injury score of the sepsis patient.

[0029] Figure 3 is a result graph of the lactobacillus nutrient composition of the application capable of reducing the ICU hospitalization time of the sepsis patient.

[0030] Figure 4 is a survival graph of the lactobacillus nutrient composition of the application capable of increasing the survival rate of the sepsis mouse.

[0031] Figure 5 is a pathological result graph of the lactobacillus nutrient composition of the application capable of inhibiting the lung inflammatory cell infiltration of the sepsis acute lung injury. The pictures are HE staining pictures of the lung tissue morphological changes of each experimental group and the control group, and the picture scale is 100 um.

[0032] Figure 6 is a lung tissue pathological score result of the lactobacillus nutrient composition of the application inhibiting the sepsis acute lung injury mouse model.

[0033] Figure 7 is a qPCR result graph of the lactobacillus nutrient composition of the application inhibiting the inflammatory factor expression of the lung tissue of the sepsis acute lung injury mouse model.

[0034] Figure 8 is a graph of the lactobacillus nutrient composition of the application capable of reducing the myeloperoxidase content in the lung tissue of the sepsis mouse. DETAILED DESCRIPTION

[0035] Following, the embodiments of the present application will be described in detail by specific examples. Other advantages and effects of the present application can be easily understood by those skilled in the art from this disclosure. The present application can also be implemented or applied by other different specific embodiments, and various modifications or changes can be made to the details in this specification based on different views and applications without departing from the spirit of the present application.

[0036] In the following examples, the low-carbohydrate high-fat nutrient, specifically TPF-T, 200 mL / bottle (fruit flavor), is produced by Fresenius Kabi China Co., Ltd., and the State Drug Standard Number is H20040722.

[0037] In the following examples, the low-carbohydrate high-fat nutrient is mixed with the mixed lactobacillus at a mass ratio of 100:1. The mixed lactobacillus includes Lactobacillus reuteri and Lactobacillus plantarum, and the mass ratio of Lactobacillus reuteri to Lactobacillus plantarum is 1:1.

[0038] Example 1: Clinical study

[0039] In a randomized, placebo-controlled clinical trial, 60 patients with sepsis combined with acute respiratory distress syndrome (ARDS) were recruited from Panyu Central Hospital Affiliated to Guangzhou Medical University. The subjects were randomly divided into control nutrient + mixed lactobacillus group (n = 15, n is the number of sepsis patients), control nutrient + placebo group (n = 15), low-carbohydrate high-fat nutrient + mixed lactobacillus group (n = 15), and low-carbohydrate high-fat nutrient + placebo group (n = 15). The mixed lactobacillus formula consists of resistant dextrin, Lactobacillus reuteri and Lactobacillus plantarum. Among them, resistant dextrin accounts for 98%, and mixed lactobacillus accounts for 2%. Each 2g of mixed lactobacillus contains 20 billion mixed lactobacillus (1:1). The placebo is only composed of resistant dextrin (100%). The low-carbohydrate high-fat nutrient + mixed lactobacillus group is the experimental group of the present application, which verifies the therapeutic effect of the lactobacillus nutrient composition proposed in the present application on sepsis.

[0040] Example 2: The lactobacillus nutrient composition of the present application can improve the oxygenation index of sepsis patients

[0041] 1. Oxygenation index observation

[0042] After the sepsis patients were admitted to the hospital, they were grouped according to the foregoing, into control nutrient + mixed lactobacillus group, control nutrient + placebo group, low-carbohydrate high-fat nutrient + mixed lactobacillus group, and low-carbohydrate high-fat nutrient + placebo group. The oxygenation index (PaO2 / FiO2) during hospitalization was observed and recorded, and the oxygenation index graph was drawn according to the recorded data.

[0043] 2. Experimental results

[0044] As shown in Figure 1 , compared with the other three groups, the oxygenation index of the patients in the low-carbohydrate high-fat nutrient + mixed lactobacillus group increased. The experimental results show that the lactobacillus nutrient composition (low-carbohydrate high-fat nutrient + mixed lactobacillus) of the present application can improve the oxygenation index of patients with sepsis.

[0045] Example 3: The lactobacillus nutrient composition of the present application can reduce the Murray lung injury score of patients with sepsis

[0046] 1. Murray lung injury score

[0047] After the sepsis patients were admitted to the hospital, they were grouped according to the foregoing, and were divided into a control nutrient + mixed lactobacillus group, a control nutrient + placebo group, a low-carbohydrate high-fat nutrient + mixed lactobacillus group, and a low-carbohydrate high-fat nutrient + placebo group. The chest X-ray performance, hypoxemia, positive end-expiratory pressure and lung compliance during hospitalization were observed and recorded, the Murray lung injury score was calculated according to the recorded data, and the Murray lung injury score result graph was drawn by statistical data.

[0048] 2. Experimental results

[0049] As shown in Figure 2 , compared with the other three groups, the Murray lung injury score of the patients in the low-carbohydrate high-fat nutrient + mixed lactobacillus group decreased. The experimental results show that the lactobacillus nutrient composition (low-carbohydrate high-fat nutrient + mixed lactobacillus) of the present application can reduce the Murray lung injury score of patients with sepsis.

[0050] Example 4: The lactobacillus nutrient composition of the present application can reduce the ICU hospitalization time of patients with sepsis

[0051] 1. ICU hospitalization time statistics

[0052] After the sepsis patients were admitted to the hospital, they were grouped according to the foregoing, and were divided into a control nutrient + mixed lactobacillus group, a control nutrient + placebo group, a low-carbohydrate high-fat nutrient + mixed lactobacillus group, and a low-carbohydrate high-fat nutrient + placebo group. The ICU hospitalization time was observed and recorded, and the ICU hospitalization time result graph was drawn according to the recorded data.

[0053] 2. Experimental results

[0054] As shown in Figure 3As shown, the ICU hospitalization time of the low-carbohydrate high-fat nutrient + mixed lactobacillus group was reduced compared with the other three groups. The experimental results show that the lactobacillus nutrient composition (low-carbohydrate high-fat nutrient + mixed lactobacillus) of the present application can obviously alleviate the symptoms of sepsis and reduce the ICU hospitalization time of sepsis patients.

[0055] Example 5: The lactobacillus nutrient composition of the present application can increase the survival rate of sepsis mice

[0056] 1. Preparation of sepsis mouse model:

[0057] 8-week-old male C57BL / 6J mice weighing 18-25g were selected and purchased from Liaoning Changsheng Biotechnology Co., Ltd. The mice were randomly divided into four groups, namely the control nutrient + mixed lactobacillus group (n=15), the control nutrient + placebo group (n=15), the low-carbohydrate high-fat nutrient + mixed lactobacillus group (n=15), and the low-carbohydrate high-fat nutrient + placebo group (n=15).

[0058] In the low-carbohydrate high-fat nutrient + mixed lactobacillus group, after 7 days of intervention with low-carbohydrate high-fat nutrient + mixed lactobacillus, the mice were modeled by cecal puncture ligation (CLP) to construct a sepsis model. Briefly, the mice were anesthetized, and the cecum was exposed by a 1-2 cm laparotomy under sterile conditions. The distal half of the cecum was ligated, and a single through-puncture was performed with an 18g needle to extrude a small amount of feces from the puncture site. Then the peritoneum was closed, and the mice were resuscitated by subcutaneous injection of 1mL sterile saline.

[0059] The control nutrient + mixed lactobacillus group, the control nutrient + placebo group, and the low-carbohydrate high-fat nutrient + placebo group were also prepared according to the above method to prepare a sepsis mouse model, except that the intervention substance was different. The low-carbohydrate high-fat nutrient + mixed lactobacillus group is the experimental group of the present application, which verifies the therapeutic effect of the lactobacillus nutrient composition proposed in the present application on sepsis.

[0060] 2. Survival rate observation

[0061] The mice after CLP modeling were placed in a mouse cage, and the 36h survival rate was observed and recorded. The survival period graph was drawn according to the recorded data.

[0062] 3. Experimental results

[0063] As shown in Table 1, the low-carbohydrate high-fat nutrient + mixed lactobacillus group had a significantly lower mortality rate than the other three groups. Figure 4As shown, the survival rate of mice in the low-carbohydrate high-fat nutrient + mixed lactobacillus group was significantly increased compared with the other three groups. The survival rate of sepsis mice in the low-carbohydrate high-fat nutrient + mixed lactobacillus group was 40% after 36h treatment. The experimental results show that the lactobacillus nutrient composition (low-carbohydrate high-fat nutrient + mixed lactobacillus) of the application can increase the survival rate of sepsis mice.

[0064] Example 6: The lactobacillus nutrient composition of the application can relieve lung inflammatory cell infiltration of sepsis mice

[0065] 1. Lung tissue paraffin section preparation:

[0066] (1) Tissue fixation: part of the fresh lung tissue of the mouse was separated and soaked in 4% paraformaldehyde fixing solution for 24h.

[0067] (2) Dehydration: dehydration was carried out according to the following procedure: 75% alcohol for 3h, 85% alcohol for 2h, 95% alcohol for 1h, 95% alcohol for 2h, anhydrous alcohol for 1h, anhydrous alcohol for 1h, environmental transparent agent for 1h, environmental transparent agent for 1h, melted paraffin for 2h, and melted paraffin for 2h.

[0068] (3) Embedding: embedding was carried out on a paraffin section embedding machine.

[0069] (4) Sectioning: sectioning was carried out on a paraffin sectioning machine, with a thickness of 4μm.

[0070] 2. HE staining

[0071] The paraffin section was placed in environmental transparent agent for 10min, environmental transparent agent for 10min, environmental transparent agent for 10min, anhydrous alcohol for 5min, 95% alcohol for 5min, 75% alcohol for 5min, and tap water for washing. The section was dyed with hematoxylin for 5min, washed with tap water, differentiated with 1% hydrochloric acid alcohol for 10s, and washed with tap water. The section was dyed with eosin for 2s, 95% ethanol for 1min, anhydrous alcohol for 1min, environmental transparent agent for 1min, and environmental transparent agent for 1min. The HE stained section was mounted with neutral resin.

[0072] 3. Photography

[0073] The prepared HE section was placed under a fluorescence inverted microscope, and 8 fields of view were randomly selected for each section at a magnification of 20X for photography.

[0074] 4. Scoring

[0075] The lung injury degree of each parameter of alveolar congestion, alveolar hemorrhage, inflammatory cell infiltration, alveolar wall thickness, etc. in each field of view was scored by blind evaluation (reference: Gong, S., Yan, Z., Liu, Z., Niu, M., Fang, H., Li, N., Huang, C., Li, L., Chen, G., Luo, H., et al. (2019). Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice. Hepatology 69, 1751-1767.). At least 6 fields of view were selected for each sample to score, and the severity of lung injury was scored 0-3 for each parameter. Including alveolar congestion, hemorrhage, inflammatory cell infiltration and alveolar wall thickness, the highest score is 12.

[0076] 5. Experimental results

[0077] As shown in Figure 5 and Figure 6 , the results of lung tissue HE staining and scoring show that compared with the other three groups, the alveolar congestion and hemorrhage in the lung tissue of the mice in the low-carbohydrate high-fat nutrient + mixed lactobacillus group are significantly reduced, the inflammatory cell infiltration around the bronchus is significantly decreased, and the alveolar wall thickness is significantly reduced. That is, the pathological score indexes of alveolar congestion, alveolar hemorrhage, inflammatory cell infiltration and alveolar wall thickness in the lung tissue of the mice in the low-carbohydrate high-fat nutrient + mixed lactobacillus group are significantly reduced. The experimental results show that the lactobacillus nutrient composition (low-carbohydrate high-fat nutrient + mixed lactobacillus) of the present application can alleviate the inflammatory cell infiltration in the lungs of sepsis mice.

[0078] Example 7: The lactobacillus nutrient composition of the present application can inhibit the expression of inflammatory factors in the lungs of sepsis mice

[0079] 1. Fluorescent quantitative qPCR detection of inflammatory factor expression:

[0080] RNA was extracted from mouse lung tissue using the phenol-chloroform extraction method. 50 mg of mouse lung tissue was mixed with 500 μL of Trizol and ground thoroughly. Then, 100 μL of chloroform was added and thoroughly mixed. The mixture was allowed to stand for 10 minutes, centrifuged at 12000 rpm for 15 minutes, and the supernatant was collected and mixed thoroughly with an equal volume of isopropanol. The mixture was allowed to stand for 10 minutes, centrifuged at 12000 rpm for 10 minutes, and the supernatant was discarded. 75% ethanol (ethanol:DEPC water = 3:1) was added and thoroughly mixed. The mixture was centrifuged at 12000 rpm for 5 minutes, and the supernatant was discarded. The remaining moisture was dried in a fume hood to obtain RNA. The RNA was reverse transcribed into cDNA. The cDNA, along with primers and fluorescent dye, was added to a PCR plate, and the expression of relevant inflammatory factors (IL-6, TNF-α, and IL-1β) was detected using a Roche quantitative PCR instrument.

[0081] 2. Experimental Results

[0082] like Figure 7 As shown, compared with the other three groups, the low-carbohydrate, high-fat + mixed lactobacillus group showed a significant decrease in the expression levels of inflammatory factors (IL-6, TNF-α, and IL-1β) in the lung tissue of mice. The results indicate that a lactobacillus nutrient composition of the present invention (low-carbohydrate, high-fat + mixed lactobacillus) can inhibit the expression of inflammatory factors in the lungs of septic mice.

[0083] Example 8: The lactobacillus nutrient composition of the present invention can inhibit the production of myeloperoxidase (MPO) in the lungs of septic mice.

[0084] 1. Measurement of myeloperoxidase (MPO) in mouse lungs:

[0085] Following the procedures outlined in the Nanjing Jiancheng myeloperoxidase (MPO) kit, 50 mg of mouse lung tissue was weighed and homogenized using the prepared reagent II solution at a weight-to-volume ratio of 1:9 to prepare a 10% tissue homogenate. Centrifugation was not required. Reagents and chromogenic solution were added in the correct proportions. After a water bath, the OD value at 460 nm was measured using a microplate reader.

[0086] 2. Experimental Results

[0087] like Figure 8 As shown, compared with the other three groups, the low-carbohydrate, high-fat + mixed lactobacillus group showed a significant decrease in myeloperoxidase (MPO) content in the lung tissue of mice. The results indicate that a lactobacillus nutrient composition of the present invention (low-carbohydrate, high-fat + mixed lactobacillus) can inhibit myeloperoxidase (MPO) production in the lungs of septic mice.

Claims

1. The application of a lactobacillus nutrient composition in the preparation of a drug for preventing and treating acute lung injury caused by sepsis, characterized in that, The lactobacillus nutrient composition is composed of low-carbohydrate, high-fat nutrients and mixed lactobacillus.

2. The application according to claim 1, characterized in that, Mix low-carbohydrate, high-fat nutrients with mixed lactobacillus at a mass ratio of 100-200:

1.

3. The application according to claim 1, characterized in that, The mixed lactobacillus is composed of resistant dextrin, Lactobacillus reuteri, and Lactobacillus plantarum, with resistant dextrin accounting for 97%-98% and mixed lactobacillus accounting for 2%-3%, wherein the mass ratio of Lactobacillus reuteri to Lactobacillus plantarum is 1:1-1.

5.

4. The application according to claim 1, characterized in that, The low-carbohydrate, high-fat nutrient has a nutritional composition of 15%-20% protein, 50%-60% fat, and 25%-35% carbohydrates.

5. The application according to claim 1, characterized in that, The lactobacillus nutrient composition can improve the oxygenation index of sepsis patients and reduce the Murray lung injury score in sepsis patients.

6. The application according to claim 1, characterized in that, The lactobacillus nutrient composition can increase the survival rate of septic mice.

7. The application according to claim 1, characterized in that, The lactobacillus nutrient composition can inhibit inflammatory cell infiltration in the lungs of septic mice with acute lung injury.

8. The application according to claim 1, characterized in that, The lactobacillus nutrient composition can inhibit the production of inflammatory factors in acute lung injury in septic mice, including IL-6, TNF-α and IL-1β.

9. The application according to claim 1, characterized in that, The lactobacillus nutrient composition can significantly inhibit the production of myeloperoxidase (MPO).

10. A drug for the prevention and treatment of acute lung injury due to sepsis, characterized in that, Includes the lactobacillus nutrient composition of claim 1 and pharmaceutically acceptable carriers, excipients, adjuvants, or combinations thereof.

Images